Caregivers should still maintain the fasting window for levothyroxine
We run comprehensive metabolic screening because were looking for the full picture: Complete hormone panel : Total testosterone, free testosterone, estradiol, DHEA, cortisol, thyroid function Metabolic markers : Insulin, glucose, lipid panel, liver and kidney function Inflammation and cardiovascular risk : CRP, homocysteine, vitamin D Tumor markers and cancer screening : PSA, CBC with differential weve caught cancers, tumors, and early-stage diseases in guys who came in just for TRT
These models provide insight into how AOD 9604 influences the partitioning of energy substrates between storage and oxidation, particularly within adipose tissue
Summary of the Interaction Profile | Feature | MK-677 | Vitamin D3 | Combined | |---|---|---|---| | Primary metabolic pathway | CYP3A4 | CYP2R1 / CYP27B1 | No shared pathway conflict | | Effect on serum calcium | Indirect increase via IGF-1/PTH | Direct increase via calcitriol | Additive, monitor | | Effect on bone markers | Increases osteocalcin, ALP | Improves mineralization | Synergistic if D is sufficient | | Insulin sensitivity | Mild decrease at 25 mg/day | May improve in deficient subjects | D correction may partially offset MK-677 effect | | Safety concern | Fasting glucose, fluid retention | Hypercalcemia at very high doses | Low risk at standard doses | | Dose separation needed | No | No | Take together with food acceptable | Frequently asked questions Can I take vitamin D while on MK-677 (Ibutamoren)
